Alexion Acquires Enobia Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Alexion Acquires Enobia Pharma



Alexion Pharmaceuticals has signed an agreement to acquire all the capital stock of the biopharmaceutical company Enobia Pharma in a $610-million all-cash transaction. The acquisition will provide Alexion with a potential treatment for patients with hypophosphatasia, a rare genetic metabolic disease that currently has no approved treatments.

"Hypophosphatasia is an ultra-rare and life-threatening disease, and those patients who survive live with debilitating morbidities including skeletal deformity, severe muscle weakness, and progressive damage to vital organs," Leonard Bell, Chief Executive Officer of Alexion, said in a statement.

Enobia Pharma’s lead product candidate for hypophosphatasia, ENB-0040 (asfotase alfa), is a human recombinant targeted alkaline phosphatase enzyme-replacement therapy. The compound is currently in Phase II clinical development, and was awarded orphan drug designation in the EU and the US in 2008 and 2009 respectively. According to the joint press statement from the companies, the compound has, to date, showed promising results in Phase II in infants and juveniles. Hypophosphatasia can affect all ages, but 50% of infant with the disease do not survive beyond one year of age.

In addition to the upfront $610 million, Alexion will also pay $470 million in cash upon achievement of various regulatory and sales milestones. The transaction has been approved by the boards of both companies and is expected to be completed in the first quarter of 2012. Alexion will finance the acquisition through cash on hand and $300 million of committed bank debt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here